文献速递自身炎症与 IgG4 相关病其他结缔组织病

FAP成像区分IgG4相关病炎症与纤维化活动

Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging.
PubMed 文献 · Ann Rheum Dis · 2020-07-21

该横断面及纵向临床研究对27例IgG4相关病患者行68Ga-FAPI-04与18F-FDG PET、MRI及组织病理评估,发现FDG阳性病灶以IgG4+浆细胞浸润为主,FAPI阳性病灶以表达FAP的活化成纤维细胞为主;纤维化病灶对抗炎治疗反应远弱于炎症病灶,提示FAP特异性PET/CT可区分炎症与纤维化活动。

要点

  • 68Ga-FAPI-04与18F-FDG PET联用可无创追踪IgG4相关病从炎症向纤维化演变。
  • FDG阳性对应IgG4+细胞密集浸润,FAPI阳性对应FAP高表达活化成纤维细胞。
  • 纤维化病灶对抗炎治疗反应远弱于炎症病灶,纤维化主导亚型或需抗纤维化治疗。

核心结论

  • FAP特异性PET/CT可区分IgG4相关病的炎症活动与纤维化活动。
  • 纤维化主导的亚型可能需特异性抗纤维化药物而非广谱抗炎治疗如糖皮质激素。

研究设计与样本

  • 横断面临床研究纳入27例具有炎症、纤维化及重叠表现的IgG4相关病患者。
  • 患者接受68Ga-FAPI-04 PET、18F-FDG PET、MRI及组织病理学评估。
  • 纵向评估免疫抑制治疗前后18F-FDG与68Ga-FAPI-04 PET/CT数据并与临床及MRI数据关联。

主要发现

  • 18F-FDG-PET阳性病灶组织学显示IgG4+细胞密集淋巴浆细胞浸润。
  • 68Ga-FAPI-04 PET阳性病灶显示大量表达FAP的活化成纤维细胞,依据为活化成纤维细胞RNA测序结果。
  • 纤维化病灶对抗炎治疗的反应远不如炎症病灶明显。

临床怎么用

  • 对IgG4相关病患者可联用68Ga-FAPI-04与18F-FDG PET/CT无创区分炎症与纤维化活动。
  • 纤维化主导的病灶对抗炎治疗反应有限,可考虑针对性抗纤维化策略而非仅用糖皮质激素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To date, there is no valuable tool to assess fibrotic disease activity in humans in vivo in a non-invasive way. This study aims to uncouple inflammatory from fibrotic disease activity in fibroinflammatory diseases such as IgG4-related disease. METHODS: In this cross-sectional clinical study, 27 patients with inflammatory, fibrotic and overlapping manifestations of IgG4-related disease underwent positron emission tomography (PET) scanning with tracers specific for fibroblast activation protein (FAP; 68Ga-FAP inhibitor (FAPI)-04), 18F-fluorodeoxyglucose (FDG), MRI and histopathological assessment. In a longitudinal approach, 18F-FDG and 68Ga-FAPI-04 PET/CT data were evaluated before and after immunosuppressive treatment and correlated to clinical and MRI data. RESULTS: Using combination of 68Ga-FAPI-04 and 18F-FDG-PET, we demonstrate that non-invasive functional tracking of IgG4-related disease evolution from inflammatory towards a fibrotic outcome becomes feasible. 18F-FDG-PET positive lesions showed dense lymphoplasmacytic infiltration of IgG4+ cells in histology, while 68Ga-FAPI-04 PET positive lesions showed abundant activated fibroblasts expressing FAP according to results from RNA-sequencing of activated fibroblasts. The responsiveness of fibrotic lesions to anti-inflammatory treatment was far less pronounced than that of inflammatory lesions. CONCLUSION: FAP-specific PET/CT permits the discrimination between inflammatory and fibrotic activity in IgG4-related disease. This finding may profoundly change the management of certain forms of immune-mediated disease, such as IgG4-related disease, as subtypes dominated by fibrosis may require different approaches to control disease progression, for example, specific antifibrotic agents rather than broad spectrum anti-inflammatory treatments such as glucocorticoids.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Schmidkonz C, Rauber S, Atzinger A, et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis. 2020. PMID: 32719042. doi:10.1136/annrheumdis-2020-217408

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。